Compare manufacturers using batch COA integrity, chemical vs enantiomeric purity, manufacturing traceability, analytical method evidence and real supply terms — not marketing claims alone.
1. Why S-Equol Supplier Qualification Is Different
S-Equol is a chiral molecule. Buyers need to establish not merely that an HPLC assay is high, but whether the supplied material is the required S configuration, how purity was calculated and whether the testing actually belongs to the proposed supply lot. Supplier marketing statements are not equivalent to objective, auditable evidence.
If you need the actual ingredient specification, use the S-Equol ≥99% HPLC product page. This guide explains how to evaluate a supplier and should not be read as proof that one company has already supplied every requested document.
2. Confirm Chemical Identity Before Price Comparisons
| Supplier claim | Buyer verification |
|---|---|
| Equol / S-Equol / R-Equol | Require precise enantiomer designation and chemical identity |
| CAS | For S-Equol, check CAS 531-95-3 |
| Purity 99% HPLC | Review method and separate enantiomeric data |
| Natural / fermentation origin | Request actual manufacturing route and feedstock documentation |
| Branded ingredient | Verify trademark owner and resale/marketing authorization |
S-Equol has the molecular formula C15H14O3 and molecular weight 242.27 g/mol. These identifiers support procurement screening; they do not establish safety authorization or verify a manufacturer’s origin claim.
3. Read the COA Without Confusing Specification and Result
A useful COA clearly distinguishes acceptance specifications from results measured for a uniquely identified lot. It also states the analytical method, manufacturing/retest dates and approving organization.
| Category | Example from an AIHerba reference COA | Interpretation |
|---|---|---|
| Purity (HPLC) | ≥99% / reported 100.0% | Method-dependent; not a no-impurities guarantee |
| Assay (dried basis) | 98.0–102.0% / 99.82% | Separate quantitative measurement |
| Specific rotation | −23.53° reported | Not itself the percentage of S-equol |
| Ethanol residual solvent | <200 ppm / 197 ppm | Within reported limit, narrow margin |
| Historical lot | YGIF26072101, 21 July 2026 | Not automatically available now |
Never take a COA from an old sample, replace its date, and call it the current commercial lot. Purchasers may request the associated chromatograms, raw data and laboratory audit trails.
4. Conventional HPLC vs. Chiral HPLC
A conventional HPLC purity result may not resolve S-Equol from R-Equol. For an S-Equol-specific purchase, ask the laboratory whether its method includes chiral separation or whether a validated orthogonal method establishes stereochemical identity.
- Batch-matched HPLC purity result and assay calculation
- Chiral resolution / S:R ratio with standards and system suitability
- Raw chromatogram, method conditions and signed review
- Impurity and residual-solvent control with traceable results
5. Reconcile TDS, Particle Size and Optical Rotation
Some products circulate with older and newer specification revisions. Differences in mesh, optical rotation, residual solvents or storage terms can be legitimate grade differences, or documentation that has not been harmonized. Neither should be guessed.
For example, a 60-mesh grade and a 100-mesh grade cannot be assumed identical even if both meet the same HPLC purity specification. Ask for a dated, signed grade-specific product specification and, where relevant, sieve curves or D10/D50/D90.
6. Examine the Manufacturing Relationship
A distributor, technical supply partner and legal manufacturer may be different entities. Request the manufacturer name and site address, then compare them with certificates, COA signatories and any upstream technical presentation. A factory brochure does not establish an exclusive partnership or grant rights to reuse protected brand and patent content.
- Exact site name and address on certificates
- Current validity and applicable scope of GMP/ISO/NSF/FSSC/Halal/Kosher where claimed
- Feedstock origin and fermentation or synthesis route declaration
- Brand or distribution authorization where a trademark is displayed
7. Request a Commercially Useful Quality Dossier
| Priority | File | Purpose |
|---|---|---|
| Essential | Current-lot signed COA | Batch-release conformity |
| Essential | Product specification / TDS | Formal agreed grade |
| Essential | Chiral HPLC or stereochemical proof | S-Equol vs R-Equol identity |
| Essential | SDS | Handling and transport |
| Important | Residual solvent + metal test reports | Regulatory risk review |
| Important | Manufacturing-site certifications | Site qualification |
| As applicable | Allergen/GMO, stability and packaging reports | Finished-formulation suitability |
Do not require every report before first contact. Start with material identity, lot/grade correspondence and applicable market requirements, and agree a phased qualification package.
8. Regulatory Screening: U.S. and European Markets
The FDA published final guidance on new dietary ingredient identity and safety information in October 2026. That guidance clarifies recommended dossier content but is not an approval of any specific S-Equol ingredient. In the EU, novelty and authorization must be evaluated in relation to the material, production route and intended food category.
FDA NDI identity and safety guidance · EU Novel Food status catalogue. A CAS entry or COA does not demonstrate market authorization.
9. Compare Price, MOQ, Lead Time and Logistics
Request comparable written quotations for the same validated assay, specified grade, unit of sale, pack size, intended destination and Incoterms. Quotes should clarify whether sampling, test reports, customs brokerage, duties or destination charges are included.
| Quote field | Suggested buyer input |
|---|---|
| Required ingredient | S-Equol ≥99% HPLC, required stereochemical identity |
| Quantity | 1 kg validation / commercial-volume request, subject to feasibility |
| Destination | Country, city or postal code for logistics |
| Technical requests | Current COA, chiral evidence, TDS and SDS |
| Terms | FOB, DAP or other agreed Incoterm; taxes clarified |
10. Supplier Qualification Decision Matrix
| Decision gate | Accept | Hold pending clarification |
|---|---|---|
| Chemical identity | CAS and stereochemical identity evidenced | Conflicting CAS / no stereochemistry |
| Batch purity | Current-lot results and method available | Reference data presented as present stock |
| Particle size | Grade and measured size agreed | 60-mesh vs 100-mesh conflict |
| Factory claims | Correct legal entity and certificates | Only marketing brochure |
| Regulatory review | Intended use and market examined | Unqualified FDA/EU approval claim |
A hold decision does not automatically mean the raw material is defective; it means the submitted supplier package is not yet sufficient for the buyer’s intended qualification.
11. Frequently Asked Buyer Questions
No. Chemical purity and enantiomeric purity require suitable methods and independent reporting.
It is useful for evaluating historical capability, but request the current actual shipment lot prior to acceptance.
No. Origin and certification claims require documentation scoped to the grade and facility.
Send a project inquiry with destination and assay requirements; quantity and lead time are subject to confirmation.
Start with the signed current-lot COA and specification, then confirm stereochemical identity evidence.
No. Regulatory status depends on the legal pathway, substance and intended use.
12. References and Sourcing Next Step
- FDA substance identity for S-Equol
- FDA 2026 NDI identity and safety guidance
- European Commission novel-food Union list
- AIHerba S-Equol 99% HPLC product technical page
- Equol identity and sources explained
Technical disclaimer: data shown as illustrative supplier documentation are historical reference values only; this article is not a statement that regulatory clearance or a specific batch supply has been confirmed.
Tell AIHerba your application, target country, required quality evidence and estimated commercial volume.
